Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Rua Bioscience Limited Capital/Financing Update 2025

Dec 7, 2025

66262_rns_2025-12-08_d95e1b5d-739f-4339-ba66-d000e81bacf7.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

PRO RATA RIGHT OFFER UPDATE

==> picture [128 x 74] intentionally omitted <==

FOR PUBLIC RELEASE

NZX Limited Wellington

8 December 2025

Update on Pro Rata Rights Offer – Commitments Secured

Rua Bioscience is pleased to provide an update on the progress of its pro rata rights offer currently open to eligible shareholders.

To date the Company has received commitments for over $1.5 million from existing shareholders, with a total of $2 million on offer. This demonstrates strong support for Rua’s strategy and the objectives of the capital raise. These commitments reflect the confidence of shareholders in the Company’s commercial progress, operational execution, and long-term growth ambitions in the global medicinal cannabis sector.

The pro rata rights offer remains open until the end of day on Friday, 12 December 2025. Any shareholder that wishes to participate should do so before this date. Full details of the offer, including the timetable and instructions on how to take up rights, are set out in the Offer Document available at www.ruabio.com/capital-raise-november-2025.

Funds raised through the Rights Offer will be applied to working capital and marketing activities to support Rua’s growth opportunities , including the launch and commercialisation of new products across key international markets such as Germany, Australia, the United Kingdom, and Czechia .

ENDS

The person who authorised this announcement:

Paul Naske Chief Executive Officer [email protected] +64 21 445154